BR112021025172A2 - Proteínas de fusão para vacinas de tuberculose - Google Patents
Proteínas de fusão para vacinas de tuberculoseInfo
- Publication number
- BR112021025172A2 BR112021025172A2 BR112021025172A BR112021025172A BR112021025172A2 BR 112021025172 A2 BR112021025172 A2 BR 112021025172A2 BR 112021025172 A BR112021025172 A BR 112021025172A BR 112021025172 A BR112021025172 A BR 112021025172A BR 112021025172 A2 BR112021025172 A2 BR 112021025172A2
- Authority
- BR
- Brazil
- Prior art keywords
- fusion proteins
- tuberculosis
- relates
- present
- vaccines
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pulmonology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
proteínas de fusão para vacinas de tuberculose. a presente invenção refere-se a proteínas de fusão baseadas em polipeptídeos antigênicos de mycobacterium tuberculosis para prevenir, inibir ou tratar infecções e/ou doenças causadas por uma espécie do complexo da tuberculose. em particular, a presente invenção refere-se a proteínas de fusão que compreendem antígenos que não iniciam uma resposta imunológica contra bcg e/ou repetições de esat-6. as proteínas de fusão podem compreender uma combinação de antígenos precoces e tardios. além disso, a presente invenção refere-se a vacinas, composições imunogênicas e composições farmacêuticas que compreendem as proteínas de fusão.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19180280 | 2019-06-14 | ||
PCT/EP2020/066343 WO2020249756A1 (en) | 2019-06-14 | 2020-06-12 | Fusion proteins for tuberculosis vaccines |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112021025172A2 true BR112021025172A2 (pt) | 2022-01-25 |
Family
ID=66999556
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112021025172A BR112021025172A2 (pt) | 2019-06-14 | 2020-06-12 | Proteínas de fusão para vacinas de tuberculose |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP3983011A1 (pt) |
KR (1) | KR20220032054A (pt) |
CN (1) | CN114222762A (pt) |
BR (1) | BR112021025172A2 (pt) |
WO (1) | WO2020249756A1 (pt) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112852848B (zh) * | 2021-03-17 | 2022-04-29 | 中国农业大学 | 一种含密码子优化的结核分枝杆菌融合蛋白ah疫苗 |
KR102666314B1 (ko) * | 2021-05-18 | 2024-05-16 | 한양대학교 에리카산학협력단 | Mpt63 및 mpt64 유래 재조합 mpt 단백질 및 이의 용도 |
CN116769056A (zh) * | 2023-07-07 | 2023-09-19 | 武汉大学 | 融合蛋白及纯化制备方法和应用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101248084B (zh) * | 2005-06-23 | 2013-11-06 | 国家血清研究中心 | 包含潜伏感染阶段期间所表达的抗原的结核疫苗 |
ES2647070T3 (es) | 2005-06-23 | 2017-12-19 | Statens Serum Institut | Vacunas para tuberculosis que comprenden antígenos expresados durante la fase de infección latente |
US20100015171A1 (en) | 2008-07-15 | 2010-01-21 | Statens Serum Institute | Vaccines comprising tb 10.4 |
JP5981138B2 (ja) * | 2008-07-25 | 2016-08-31 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 結核Rv2386cタンパク質、組成物およびその使用 |
JP6333814B2 (ja) * | 2012-07-10 | 2018-05-30 | トランジェーヌ、ソシエテ、アノニムTransgene S.A. | マイコバクテリア抗原ワクチン |
JP6470179B2 (ja) * | 2012-10-23 | 2019-02-13 | スタテンス セールム インスティトゥート | 結核菌(m.tuberculosis)ワクチン |
CN106232138A (zh) * | 2014-04-24 | 2016-12-14 | 国家血清研究所 | 新型结核分枝杆菌疫苗 |
-
2020
- 2020-06-12 WO PCT/EP2020/066343 patent/WO2020249756A1/en unknown
- 2020-06-12 CN CN202080056859.8A patent/CN114222762A/zh active Pending
- 2020-06-12 KR KR1020227001213A patent/KR20220032054A/ko unknown
- 2020-06-12 EP EP20731142.4A patent/EP3983011A1/en active Pending
- 2020-06-12 BR BR112021025172A patent/BR112021025172A2/pt unknown
Also Published As
Publication number | Publication date |
---|---|
CN114222762A (zh) | 2022-03-22 |
EP3983011A1 (en) | 2022-04-20 |
KR20220032054A (ko) | 2022-03-15 |
WO2020249756A1 (en) | 2020-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112021025172A2 (pt) | Proteínas de fusão para vacinas de tuberculose | |
BR112018013387A2 (pt) | vetor de vacinação recombinante, vírus mva, vacina ou composição farmacêutica e kit | |
MX351074B (es) | Vacunas contra clostridium difficile que comprenden toxinas recombinantes. | |
EP3616716A3 (en) | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | |
BR112017008165A2 (pt) | anticorpos de domínio único direcionados contra antígenos intracelulares | |
EA201890355A1 (ru) | Новые способы индукции иммунного ответа | |
BR112016015422A2 (pt) | formulações de vacina de frasco único | |
BR112015009070A2 (pt) | proteína de fusão ou coquetel de antígenos; uso de uma proteína de fusão ou um coquetel de antígenos; vacina; e método para imunizar um animal, que inclui um ser humano, contra tuberculose causada por microbactérias virulentas | |
BR112016023778A2 (pt) | proteína de fusão ou coquetel antígeno, uso de uma proteína de fusão ou coquetel antígeno, vacina, e método para a imunização de um animal, incluindo um ser humano, contra a tuberculose causada por micobactérias virulentas | |
BR112018075440A2 (pt) | composições e métodos para prevenir e tratar a infecção por zika vírus | |
BR112019008844A2 (pt) | conjugado de proteína de polissacarídeo imunogênico compreendendo um polissacarídeo derivado de b. streptococcus gbs | |
BR112015004593A2 (pt) | composições imunogênicas | |
BR112018076234A2 (pt) | vacina contra o vírus da bronquite infecciosa | |
PH12015501716A1 (en) | Anti-mycoplasma spp. subunit vaccine | |
EA202091690A1 (ru) | Иммуногенная композиция, содержащая стафилококковые антигены | |
WO2017142843A8 (en) | Novel antigen for use in malaria vaccine | |
WO2016191641A3 (en) | Methods for enhancing antigen-specific immune responses using combination therapy comprising papillomavirus capsid antigens | |
BR112017002440A2 (pt) | vírus da diarreia epizoótica porcina mutante para utilização em uma vacina | |
BR112019004303A2 (pt) | composição de conjugados multivalentes de polissacarídeo capsular pneumocócico-proteína portadora e uso da mesma | |
HRP20180039T1 (hr) | Antigeni pseudomonasa i kombinacije antigena | |
BR112014020025A2 (pt) | vacinas de subunidade de rotavirus e métodos de produção e uso das mesmas | |
BR112018074910A2 (pt) | composição imunológica, e, método de indução de uma resposta imunológica contra o vírus da influenza equina em um sujeito | |
BR112018071965A2 (pt) | tratamento da dermatite atópica canina | |
AR104271A1 (es) | Vacuna contra las paperas en base al virus jeryl lynn 2 recombinante | |
BR112018005581A2 (pt) | peptídeo derivado de foxm1 e vacina incluindo o mesmo |